BW

05
Jun
By MetroLatinoUSA
BW

PentaFour Acquires Winterhawk Consulting from Pathlock

The purchase of the company’s business and assets strengthens PentaFour’s position as the preferred conglomerate of ERP & GRC Solutions Provider for the Enterprises. SOMERSET, N.J.--(BUSINESS WIRE)--#ERP--PentaFour Solutions, LLC (“PentaFour”) the “Tech 360 for the Enterprises” company, announces the acquisition of the business and assets of Winterhawk Consulting (“WHC”), a…
Leer más...
05
Jun
By MetroLatinoUSA
BW

Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project

Data show MammaPrint® is the first and most comprehensive FDA-cleared test for early breast cancer resulting in the ability to identify women who may be over- or under-treated if treatment decisions relied on the 21-gene assay FLEX Trial continues to support the discovery and development of novel genomic profiles, bringing…
Leer más...
05
Jun
By MetroLatinoUSA
BW

NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications

Data reported at the 2022 Annual Meeting of the American Society for Clinical Oncology NBTXR3 is being developed as a product candidate with potential to integrate across the standards of care in oncology, and these data from collaborator-sponsored phase 1b/2 studies add support for the radioenhancer in combination with chemoradiation…
Leer más...
05
Jun
By MetroLatinoUSA
BW

CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies

- CYT-0851 has demonstrated broad clinical activity and a generally well tolerated safety profile in a heavily pretreated population of patients - Durable responses seen in both solid tumors and hematologic malignancies in the dose escalation with a 44% disease control rate in the response-evaluable population - Safety and clinical…
Leer más...
05
Jun
By MetroLatinoUSA
BW

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease

AstraZeneca and Daiichi Sankyo’s ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients evaluated in DESTINY-Breast04 ENHERTU met the primary endpoint of progression-free survival in patients with HR-positive disease, reducing the risk of disease progression or death by 49% vs. chemotherapy ENHERTU is…
Leer más...
05
Jun
By MetroLatinoUSA
BW

Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New Study

New research from Gelesis highlights ongoing stigmatization of people with obesity and diabetes BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, presented new findings about the role of language in obesity and diabetes scientific literature at the American Diabetes Association’s annual conference. The study sought to understand…
Leer más...
05
Jun
By MetroLatinoUSA
BW

Foundation Medicine Announces Strategic Collaboration with Arvinas

Initial Goal of Collaboration is to Develop FoundationOne®Liquid CDx as a Companion Diagnostic for Bavdegalutamide (ARV-110), Arvinas’ Investigational Androgen Receptor-Targeting PROTAC® Protein Degrader CAMBRIDGE, Mass.--(BUSINESS WIRE)--#ASCO22--Today Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, announced a collaboration with Arvinas, Inc., to develop FoundationOne®Liquid CDx as a companion diagnostic…
Leer más...
05
Jun
By MetroLatinoUSA
BW

ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

Daiichi Sankyo and AstraZeneca’s ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients evaluated in DESTINY-Breast04 ENHERTU met the primary endpoint of progression free survival in patients with HR positive disease, reducing the risk of disease progression or death by 49% vs. chemotherapy…
Leer más...
05
Jun
By MetroLatinoUSA
BW

Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial

KEYNOTE-716 is the first Phase 3 trial with an anti-PD-1/L1 to significantly improve distant metastasis-free survival (DMFS) and recurrence-free survival (RFS) for these patients Based on KEYNOTE-716, KEYTRUDA received US FDA approval and a positive EU CHMP opinion for the adjuvant treatment of patients aged 12 and older with completely…
Leer más...
¡Síguenos en Facebook!
¡Síguenos en Twitter!